151751-Najiba-Chargi

CHAPTER 1 General introduction Aim and outline of this thesis	11
CHAPTER 2 Validation of skeletal muscle mass assessment at the level of the third cervical vertebra in patients with head and neck cancer	31
CHAPTER 3 Agreement between skeletal muscle mass measurements using computed tomography imaging and magnetic resonance imaging in head and neck cancer patients	45
CHAPTER 4 The association of muscle segmentation of the musculus masseter and muscle segmentation at the level of the third cervical and lumbar vertebrae	53
CHAPTER 5 Cut-off values for low skeletal muscle mass at the level of C3 in patients with head and neck cancer	75
CHAPTER 6 Low skeletal muscle mass is a strong predictive factor for surgical complications and prognostic factor for survival in oral cancer patients undergoing mandibular reconstruction with a free fibula flap	93
CHAPTER 7 Association of low skeletal muscle mass and systemic inflammation with surgical complications and survival after microvascular free flap head and neck reconstruction	111
CHAPTER 8 Are perioperative complications in patients operated for oral squamous cell carcinoma associated with low skeletal muscle mass?	141
CHAPTER 9 Arterial calcification and low skeletal muscle mass are independent risk factors for pharyngocutaeneous fistula formation after total laryngectomy	157
CHAPTER 10 Image-based analysis of skeletal muscle mass predicts cisplatin dose-limiting toxicity in patients with locally advanced head and neck cancer	179
CHAPTER 11 Pre-treatment low skeletal muscle mass is associated with chemotherapy dose-limiting toxicity in head and neck cancer patients undergoing primary chemoradiotherapy with high dose cisplatin	197
CHAPTER 12 The predictive and prognostic value of low skeletal muscle mass for doselimiting toxicity and survival in head and neck cancer patients receiving concomitant cetuximab and radiotherapy	217
CHAPTER 13 The predictive value of low skeletal muscle mass assessed on cross-sectional imaging for anti-cancer drug toxicity: a systematic review and meta-analysis	235
CHAPTER 14 The association of cisplatin pharmacokinetics and skeletal muscle mass in head and neck cancer: the prospective PLATISMA study	257
CHAPTER 15 Patterns, predictors and prognostic value of skeletal muscle mass loss in patients with locally advanced head and neck cancer undergoing cisplatinbased chemoradiotherapy	273
CHAPTER 16 Skeletal muscle mass is an imaging biomarker for decreased survival in patients with oropharyngeal squamous cell carcinoma	293
CHAPTER 17 Dysphagia, trismus and speech impairment following radiation-based treatment for advanced stage oropharyngeal carcinoma: a one-year prospective evaluation	313
CHAPTER 18 Sarcopenia is a prognostic factor for overall survival in elderly patients with head and neck cancer	361
CHAPTER 19 Sarcopenia measured with handgrip strength and skeletal muscle mass to assess frailty in older patients with head and neck cancer	381
CHAPTER 20 Low skeletal muscle mass predicts frailty in elderly head and neck cancer patients	401
CHAPTER 21 Summarizing discussion General discussion and future perspectives	421
CHAPTER 22 Nederlandse samenvatting	440
About the author	451
Dankwoord	452

Made with FlippingBook

RkJQdWJsaXNoZXIy ODAyMDc0